Finance

Lists
Why is ARQT up 2.65%?
Dive Deeper
ARQT:NASDAQ
Arcutis Biotherapeutics Inc
$28.26
+2.65%
(+0.73) 1D
Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ARQT...
Open
$27.50
High
$28.33
Low
$27.06
Mkt. cap
3.57B
Avg. vol.
2.49M
Volume
858.23K
P/E ratio
126.69
52-wk high
$34.80
52-wk low
$19.30
EPS
$0.22
Beta
1.66
Shares outstanding
126.46M
No. of employees
354
Open
$27.50
High
$28.33
Low
$27.06
Mkt. cap
3.57B
Avg. vol.
2.49M
Volume
858.23K
P/E ratio
126.69
52-wk high
$34.80
52-wk low
$19.30
EPS
$0.22
Beta
1.66
Shares outstanding
126.46M
No. of employees
354
News stories
From web sources and news partners
About Arcutis Biotherapeutics Inc
CEOFrank Watanabe
Employees354
Founded2016
HeadquartersWestlake Village, California, United States
SectorHealth Care
IndustryBiotechnology
Analyst ratings
Based on 5 analysts giving stock ratings to ARQT in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for ARQT in the last 3 months.
Highest
Current $28.26
$48.00 (+69.85%)
Average
$42.00 (+48.62%)
Lowest
$38.00 (+34.47%)
Analyst
Recommendation
Action
Price target
Projected
Date
Tyler Van Buren
TD Cowen
Buy
Reiterated
$40.00
+41.5%
11/04/2026
Michael Ulz
Morgan Stanley
Buy
Maintained
$38.00
+34.5%
11/05/2026
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
$40.00
+41.5%
11/05/2026
Seamus Fernandez
Guggenheim
Buy
Reiterated
$44.00
+55.7%
10/19/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Initiated
$48.00
+69.9%
10/15/2026
Judah Frommer
Morgan Stanley
Buy
Reiterated
$38.00
+34.5%
08/06/2026
Serge Belanger
Needham
Buy
Reiterated
$40.00
+41.5%
08/06/2026
Uy Ear
Mizuho Securities
Buy
Reiterated
$36.00
+27.4%
08/06/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$35.00
+23.8%
07/16/2026
Unknown Analyst
Jefferies
Buy
Maintained
$35.00
+23.8%
07/09/2026
Richard Law CFA
Goldman Sachs
Hold
Maintained
$33.00
+16.8%
02/27/2026
Last report
Nov 4, 2026
Fiscal period
Q3 2026
$0.06 / $0.17
-64.36%miss
Revenue / Est. (USD)
143.92M / 142.59M
+0.93%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
129.50M
105.40M
129.86M
143.92M
Cost of goods sold
11.69M
9.78M
10.94M
12.46M
Cost of revenue
11.69M
9.78M
10.94M
12.46M
Research and development expenses
20.45M
30.63M
20.36M
22.42M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
78.98M
74.08M
82.14M
99.60M
Operating expense
99.43M
104.70M
102.49M
122.02M
Total operating expenses
111.12M
114.49M
113.43M
134.48M
Operating income
18.39M
-9.09M
16.43M
9.44M
Other non operating income
-6.42M
-20.00K
-157.00K
-77.00K
EBT including unusual items
17.86M
-11.20M
15.14M
9.00M
EBT excluding unusual items
17.86M
-11.20M
15.14M
9.00M
Income tax expense
470.00K
93.00K
136.00K
195.00K
Effective tax rate
2.63%
-0.83%
0.90%
2.17%
Other operating expenses
-
-
-
-
Net income
17.40M
-11.30M
15.01M
8.80M
Net profit margin
13.43%
-10.72%
11.56%
6.12%
Earnings per share
0.13
-0.09
0.11
0.06
Interest and investment income
8.90M
2.28M
2.28M
2.60M
Interest expense
-3.00M
-4.37M
-3.41M
-2.96M
Net interest expenses
5.90M
-2.09M
-1.13M
-363.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
18.95M
-8.53M
16.99M
10.00M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps